It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Trehalose is the nonreducing disaccharide of glucose, evolutionarily conserved in invertebrates. The living skin equivalent (LSE) is an organotypic coculture containing keratinocytes cultivated on fibroblast-populated dermal substitutes. We demonstrated that human primary fibroblasts treated with highly concentrated trehalose promote significantly extensive spread of the epidermal layer of LSE without any deleterious effects. The RNA-seq analysis of trehalose-treated 2D and 3D fibroblasts at early time points revealed the involvement of the CDKN1A pathway, the knockdown of which significantly suppressed the upregulation of DPT, ANGPT2, VEGFA, EREG, and FGF2. The trehalose-treated fibroblasts were positive for senescence-associated β-galactosidase. Finally, transplantation of the dermal substitute with trehalose-treated fibroblasts accelerated wound closure and increased capillary formation significantly in the experimental mouse wounds in vivo, which was canceled by the CDKN1A knockdown. These data indicate that high-concentration trehalose can induce the senescence-like state in fibroblasts via CDKN1A/p21, which may be therapeutically useful for optimal wound repair.
Highly concentrated trehalose induces beneficial senescence-like state in fibroblasts and accelerates the proliferation of keratinocytes and angiogenesis to promote optimal wound repair, demonstrating its therapeutic potential in modulating fibroblast functions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Ehime University Graduate School of Medicine, Department of Dermatology, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808)
2 Aichi Gakuin University, Department of Biochemistry, School of Dentistry, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594)
3 Yamaguchi University Science Research Center, Institute of Gene Research, Yamaguchi, Japan (GRID:grid.268397.1) (ISNI:0000 0001 0660 7960)
4 Kanazawa Medical University, Department of Pharmacology, School of Medicine, Uchinada, Japan (GRID:grid.411998.c) (ISNI:0000 0001 0265 5359)
5 Ehime University Graduate School of Medicine, Department of Molecular Medicine for Pathogenesis, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808)
6 Ehime University Graduate School of Medicine, Department of Molecular Medicine for Pathogenesis, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808); Ehime University Hospital, Translational Research Center, Toon, Japan (GRID:grid.452478.8) (ISNI:0000 0004 0621 7227)
7 Ehime University, Division of Cell Growth and Tumor Regulation, Proteo-Science Center, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808); Osaka International Cancer Institute, Department of Molecular and Cellular Biology, Osaka, Japan (GRID:grid.489169.b) (ISNI:0000 0004 8511 4444)